Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.33 |
| ▸ | FEN1 | P39748 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14218717 | 0.88 | ALOX5AP (0.39) | MDM2ALOX5APFEN1ABL1PTGES | |
| SCHEMBL5140205 | 0.88 | RORC (0.30) | RORC | |
| SCHEMBL14218913 | 0.88 | MDM2 (0.42) | MDM2ABL1KMO | |
| SCHEMBL14218912 | 0.87 | GRM2 (0.37) | MDM2ALOX5APFEN1ABL1 | |
| SCHEMBL14218663 | 0.84 | MDM2 (0.36) | MDM2ALOX5APFEN1ABL1PTGES | |
| SCHEMBL13135163 | 0.78 | PTGS2 (0.37) | ALOX5APFEN1ABL1ALDH1A1RAB9A | |
| SCHEMBL14218664 | 0.76 | ADORA1 (0.36) | ABL1GCGR | |
| SCHEMBL5109023 | 0.76 | POLB (0.36) | RORC | |
| SCHEMBL5109371 | 0.74 | MAPK1 (0.33) | MDM2 | |
| SCHEMBL13135162 | 0.72 | MOGAT2 (0.36) | MDM2ALOX5APFEN1ABL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375108-B2 | 2-substituted pyrimidines | BASF AKTIENGESELLSCHAFT (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20070105873-A1 | 2-Substituted pyrimidines | BASF AKTIENGESELLSCHAFT (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105873-A1 | 2-Substituted pyrimidines | TYMP, RRM2, TYMS | MDM2 359/4885ALOX5AP 3381/4885FEN1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.